Neuromodulation Devices Market - Global Industry Size, Market Share, Trends, Analysis, And Forecast 2012 - 2018


According to a new market report published by Transparency Market Research  "Neuromodulation Devices Market - Global Industry Analysis, Size, Share and Forecast, 2012 - 2018," the global neuromodulation devices market was valued at USD 2,758 million in 2011 and is expected to grow at a CAGR of 14.4% from 2012 to 2018, to reach an estimated value of USD 7,072.6 million by 2018.

The market is driven by factors such as the aging world population leading to chronic diseases such as Parkinson's and Alzheimer's disorders and technological advancements in the field of neuromodulation devices including the invention of transdermal neuromodulation technology by NMT (Neurowave Medical Technologies). Moreover, the rising prevalence of chronic diseases, increasing demand for minimally invasive surgeries, the availability of external funding to conduct clinical studies to help come up with new and technologically advanced products and the rising healthcare related consumer expenditure have also driven the growth in this market. The fact that a neuromodulation device could be used as an add-on treatment and so can be used simultaneously with other medications also drives the market forward.

The North American region holds majority of the market share and accounted for a share of 65% in 2011. The North American neuromodulation device market was valued at USD 1,792.7 million in 2011. The economic developments in the Asia Pacific region make it the fastest growing region (CAGR of more than 15% from 2012 to 2018) in the neuromodulation devices market.

The future growth of the market will be ensured by capitalizing on market opportunities such as increasing healthcare related consumer expenditure in emerging economies in the Asia Pacific, Latin American and Eastern European regions. The availability of medical device manufacturing outsourcing options helps in curbing costs and thereby enhances profit margins. Also, the presence of consolidation options in the healthcare industry helps in strengthening the revenue base to conduct R&D exercises for new product development and thus helps in strengthening market share.

Implementation of the Affordable Healthcare for America Act, 2010 which imposes an excise tax of 2.5% on medical devices and the stringent FDA regulations are some of the factors restraining the growth of the market. Risks involved in using a neuromodulation device such as injury to the vagus nerve and nearby blood vessels (carotid artery and jugular vein) in case of a vagus nerve pacemaker also impedes the growth of the market.

Neuromodulation Devices Market by Technology

    • Spinal Cord Stimulation Devices
    • Deep Brain Stimulation Devices
    • Vagus Nerve Stimulation Devices
    • Sacral Nerve Stimulation Devices
    • Gastric Electric Stimulation Devices

Neuromodulation Systems for Different Application Areas

    • Medtronic's Spinal Cord and Deep Brain Neurostimulation Systems
    • St. Jude Medical's Eon  Mini Neurostimulator System
    • Boston Scientific's Precision Spinal Cord Stimulation System
    • Nevro's Senza System for Spinal Cord Stimulation
    • Cyberonics' VNS Therapy System
    • Codman & Shurtleff's Medstream system
    • Medtronic's Enterra™ Therapy System
    • IntraPace's abiliti system

Neuromodulation Devices Market by Geography

    • North America
    • Europe
    • Asia Pacific
    • RoW (Rest of the World)

» Read More...

CINV Existing & Pipeline Drugs (Aloxi, Emend, Netupitant-Palonosetron Fdc, Apf530 & Rolapitant) Market - Global Market Opportunity Assessment Study, 2012 - 2018

According to a new market report published by Transparency Market Research "CINV Existing & Pipeline Drugs (Aloxi, Emend, Netupitant-Palonosetron FDC, APF530 & Rolapitant) Market - Global Market Opportunity Assessment Study, 2012 - 2018," the global CINV market was worth USD 1.3 billion in 2011 and is expected to reach USD 2.1 billion in 2018, growing at a CAGR of 7.1% from 2013 to 2018. The North American CINV existing and pipeline drugs market is expected to reach USD 1.0 billion in 2018. Sluggish economic growth and a poor reimbursement scenario in European countries have hampered the growth of CINV drugs market in these 
regions.

Nausea and vomiting represent the most frequent side-effects experienced by chemotherapy patients, referred to as chemotherapy-induced nausea and vomiting (CINV) Market, which is debilitating to cancer patients. Emetogenic refers to the likelihood of a chemotherapy drug affecting the patient in an adverse manner, leading to added illness or sickness. Highly emetogenic chemotherapy (HEC) mostly leads to nausea and vomiting in 90% or more of the cases, while moderately emetogenic chemotherapy (MEC) causes nausea and vomiting in 30-90% of the cases.

Current drug treatments available to prevent CINV have failed to completely overcome the symptoms of this disease. Moreover, most of the drugs are approved for acute-onset CINV whereas there is no drug approved yet for delayed-onset CINV for patients receiving HEC, which occurs more frequently (50-70% of patients) in the cancer population.

The inefficiency to effectively predict CINV incidence and understand the complex physiology of CINV by healthcare providers coupled with the failure to adhere to recommended guidelines, have been prominent reasons for deficiency in CINV treatment.However, the current pipeline in the CINV market offers huge potential to overcome such unmet needs, with better and efficient drugs for both acute and the more prominent, delayed-onset CINV.

Netu-palo FDC of Helsinn Healthcare, currently in phase III trials, which was in-licensed by the Helsinn group from Roche in the year 2005, helps in preventing CINV in acute as well as delayed-onset CINV patients. Due to its combination of a 5-HT3 antagonist and an NK-1 antagonist, the netu-palo FDC helps in overcoming unmet needs existing with current drug treatments available, which are mostly 5-HT3 antagonists. Moreover, other drugs in the pipeline, namely, APF530 and rolapitant offer physicians alternative treatment options for patients who show little relief from existing drugs in the market.

This research is specially designed to estimate and analyze the demand and performance of the CINV pipeline drugs in a global scenario. The research provides in-depth analysis of CINV pipeline drugs manufacturers, product sales, trend analysis by segments and demand by geography. The report covers all the major product segments of the global CINV pipeline drugs market and provides detailed analysis, historical data and statistically refined forecast for the segments covered. 

The study presents a comprehensive assessment of the stakeholder strategies, winning imperatives for them by segmenting the global CINV pipeline drugs market as below:

  • CINV - Pipeline Products APF530 (long-acting granisetron - 5-Ht3RA)
  • Efficacy Results of APF530 MEC Phase III Study
  • Efficacy Results of APF530 HEC Phase III Study Rolapitant (NK-1-RA)
  • Chemical structure of rolapitant
  • Netupitant-Palonosetron FDC
  • Introduction
  • Mechanism of action
  • Chemical structure of netupitant
  • Unmet Needs in the CINV Market
  • Clinical Trial Details for CINV pipeline drugs APF530
  • Clinical Trial: ID- NCT00343460 Rolapitant
  • Clinical Trial: ID - NCT01500226
  • Clinical Trial: ID - NCT01500213
  • Clinical Trial: ID - NCT01499849 Netupitant-palonosetron FDC
  • Clinical Trial: ID - NCT01376297
  • Clinical Trial: ID - NCT01339260


In addition the report provides a cross-sectional analysis of all the above segments with respect to the following geographical markets:

  • North America
  • Europe

» Read More...

Search This Blog

About Me

My photo

The dedicated team of researchers and analysts at Business Research Industry into the Advantage of Knowledge for your company. Data becomes knowledge through the application of Dolcera's optimization process as follows.

Archives

Business Research Industry. Powered by Blogger.